Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Herbalife Nutrition Ltd (HLF) vs Pfizer Inc (PFE) Price & Performance

Herbalife Nutrition LtdTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Herbalife Nutrition Ltd vs Pfizer Inc — how do they compare? Herbalife Nutrition Ltd trades at $11.71 (market cap $1.23B), while Pfizer Inc trades at $26.29 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 123.4× Herbalife Nutrition Ltd's market cap, and Pfizer Inc pays a 6.46% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals.

HLFPFE
Market Cap
$1.23B$151.73B
Sector
Consumer StaplesHealth
52-Week High
$19.96$28.56
52-Week Low
$7.75$23.60
Enterprise Value
$3.06B$203.22B
Volume
29,869,932
Dividend Yield
6.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Herbalife Nutrition Ltd

HLF trades at $11.71, up 1.65% on the day, with a bearish technical signal from moving averages. The company shows mixed earnings, missing Q2 2026 EPS estimates but achieving four consecutive quarters of sales growth. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24, though negative shareholder equity and high debt levels present financial risks. Recent news includes a planned CFO transition and inclusion in TIME's America's Best Companies 2026 list.

The outlook for HLF balances low valuation against operational and financial challenges. Investment opportunity lies in potential margin improvement and debt reduction, but risks include earnings volatility, high leverage, and competitive pressures in the nutrition space. Analyst sentiment is cautiously optimistic with a majority buy rating.

Pfizer Inc

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Herbalife Nutrition Ltd

Herbalife Nutrition Ltd is an international nutrition company.

Read more on HLF

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE